Member Info for xviolet

Share price goes down

could easily go up again. in time.

i've been doing more and more research - its always hard when you're got a full-time job. And...not losing any sleep on holding this, just give it time. so much info in all the newsletters and letters to shareholders - info re cash position - eg how the company is moving towards being more cash generative. I just think some of us get carried away re share price and possible multiples, meanwhile the company makes nice, steady progress. and when they turn to their hand to something new - eg GaM trial - they end up being fast tracked by the FDA. these people clearly know what they are doing.

I did buy a few today. As promised really.

Just read the news - the houthis are being a bit more amen-able...

who knows. 2 many unknowns. but the odd small buy...what the hell....why not.

The news-flow here looks like they orchestrated it.. And there may well be more and more to come. It can't be an easy stock to dump at the end of the week. An exciting share. And we're still only in January.

Just decided....or remembered...that its probably best not to think about this as a trading share

buy some. forget about them. its 2 tangled (for me) to see clearly. will trade some others.

added a few anyway.

Un-stoppable

maybe now lunch is over.

150mcap in time. or more.

I had been thinking the shift to the next stage of the trial would be something to focus minds over at IQ towers - then I did some research (always helps) - Phase 1 doesn't finish for a while - like primary completion 12/25 (presume that means xmas 25) and study completion (12/26).

https://clinicaltrials.gov/study/NCT04319276

as always please let me know if I got something wrong re the above. and one question - anyone confident they 'don't' need to raise a few £? anyone been going over the funding, balance sheets etc and joined a few dots?

Everything here could be nice and simple - they issue a few more CLNs because the company needs some cash. And then we will see the share price move back to a new place as everyone is more secure about whats going on. Deal with GE, fast track FDA etc - lots of promising material in the offing and if just needs a few 100K to bump things along...why not?

Or maybe the company doesn't need any cash and something else is happening as they cut a deal/JV to fund the next stage of the trials. If its not a licensing deal - and even if it is - it means change. Maybe some could hazard a guess. And if TB wants to keep 29 per cent - how will that be managed in the JV if the incoming partner wants shares for their millions of dollars input. I guess there are all sorts of tangles and possibilities.

I googled it. All shipping costs are up at the moment.

All. Not just red sea related.

Sadly.

But...our sales are bound to be up and hopefully a lot of inventory is already in place...these issues are never simple. The company could give us an update. But I can also see how this can create interesting buying opportunities.

Just checked the other grant was for $50,000 as well. Not bad, I guess.

By the way anyone done the maths on how much TB and FAB would have made from recent CLN sales - is it more than £250K? Enough to fund the next set of CLNs?

So the funding was for $50,000. Thats one of them anyway. Is that why they didn't RNS it...because the cost of producing the RNS meant it wasn't worth it? Should have tweeted it thought. Even though its not a huge amount.

https://ahwendowment.org/AHW/Health-Focused-Research/Characterization-of-Response-to-Gallium-Maltolate-in-Treatment-Resistant-Glioblastoma.htm

I think TR1s can d*ck around - buying and selling inside their holding and report much later or not report at all if after a while the numbers are more or less unchanged. Thats what I've heard.

Tyke...

yes this is looking very positive.

But I would like to see more info re the sales from GE and Bayer. They are very good at tweeting stuff - tweet some £ deals please. From time to time.

Re...

'Plus anything else we aren’t aware of yet'

sales/commercial contracts. thats what I would like to see. and details of the next stage of the trial eg license or JV with larger pharma/comp. that would be very welcome.

Different perspectives from different posters - truth is out there. Somewhere.

Selling cheap? TB is making a profit, I think. And they were an unsecured loan. May 2019 RNS says 1.5p for this stock. And once these CLNs are gone he might need to issue more if IQAI needs more capital. However the May 2019 RNS says these CLNs were for 'working capital for product development' but the annual report said the CLNs were used (amongst other funds) to for 'day to day working capital'. And he has to stay under 30 per cent so he has to sell.

No doubt some on this board have a better understanding of this. I look forwards to being corrected.

Thanks Tyke. So if we assume they are in 'concert' that is interesting. Especially if it comes to the question of funding for a Phase 2 or then a later Phase 3 trial. IQAI said that funding would come 'substantially' from grants and a partnership with a large pharma - but that could leave a small shortfall and also the question of what the large pharma would ask for in return esp if TB and FAB want to keep owning the same percentage of the company. Anyone given this some thought?

Re takeover rules - are TB and FAB's stakes considered as 'acting in concert' acc to city code on takeover and mergers or could, in theory FAB go up to 29 per cent as well?

Coming down the line?

it would be business as usual if it weren't for that trial and proposed JV. I suppose the latter must have an impact on the finances/ownership/register etc - not sure what. perhaps some others have a better idea.

Thanks Tyke

So out of 16 million that's about 10 million down. I was just going to go through the RNS's but you saved me the trouble.

We think this is beyond TB's usual CLNs and shuffling of resources? I haven't kept up to date with how many CLNs he has left.